← Leaderboards
Zitadel Anne Perez Esguerra
University Of Southern California
$128,070
Attributed
$128,070
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $43.2K · FY2016–18$50K$37.5K$25K$12.5K$0
'16
'17
'18
Funding mix
By agency
NIH$128,070 · 1
By mechanism
F31$128,070 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Michael R Lieber$20,714,841
- Myron Fredric Goodman$33,678,481
- Smita Bhatia$27,398,641
- Joseph Leo Wiemels$16,840,536
- Lucio Comai$7,724,758
Others in their field
Top investigators on “Acute Lymphocytic Leukemia”
- Gregory H Reaman · National Childhood Cancer Foundation$49,776,131
- Markus Mãschen · Yale University$23,102,071
- Mary V. Relling · St. Jude Children'S Research Hospital$19,973,747
- John F Dipersio · Washington University$18,970,493
- William E. Evans · St. Jude Children'S Research Hospital$16,917,007
- Bruce R. Blazar · University Of Minnesota$16,394,527
Research focus
Acute Lymphocytic LeukemiaAdultAdverse EffectsAffectAmino AcidsAntibodiesAntibody DiversityArtemisBaseB-Cell Acute LeukemiaBeta-LactamaseBindingBiochemicalB-LymphocytesBone MarrowBone Marrow CellsBone Marrow TransplantationBuffersCancer CellCatalytic DomainCell DeathCell ProliferationCellsActive Sites
Grant awards (3)
Developing an Artemis Nuclease Inhibitor to Potentially Treat Acute Lymphoblastic Leukemia$43,166
F31 · FY2018 · GM · contact PI
Developing an Artemis Nuclease Inhibitor to Potentially Treat Acute Lymphoblastic Leukemia$42,686
F31 · FY2017 · GM · contact PI
Developing an Artemis Nuclease Inhibitor to Potentially Treat Acute Lymphoblastic Leukemia$42,218
F31 · FY2016 · GM · contact PI